Skip to main content
SpringerLink
Log in
Book cover

Introduction to Gastrointestinal Diseases Vol. 2 pp 39–51Cite as

Pharmacological Treatment of Peptic Ulcer Disease

  • Chapter
  • First Online:

Abstract

Peptic ulcer disease (PUD) is an upper gastrointestinal (GI) disorder with complex etiology, which is a growing major concern worldwide. The pathophysiology of PUD is relatively well understood, hence there are several specific treatment options for this disorder aiming at various pharmacological targets located in the GI tract. In this chapter we provide an overview on pharmacological targets as well as drugs that are currently available for PUD therapy with regard to the etiology of the disease. We discuss their mechanisms of action, evidences for their effectiveness emerging from clinical trials as well as virtues and drawbacks of the most commonly prescribed medications. Furthermore, we highlight the practical aspects of the use of drugs in PUD, such as dosing regimens, resistance issues, possible adverse events, and contraindications.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

CAM:

Complementary and alternative medicine

cAMP:

Cyclic AMP

COX:

Cyclooxygenase

EP:

Prostaglandin type E receptor

GI:

Gastrointestinal

GPCR:

G protein-coupled receptor

H+/K+ ATPase:

Proton pump

H2:

Histamine type 2 receptors

NSAIDs:

Non-steroidal anti-inflammatory drugs

PPI:

Proton pump inhibitor

PUD:

Peptic ulcer disease

TNFα:

Tumor necrosis factor α

Reference

  1. Kobayashi T, Inoue I, Jenkins NA, Gilbert DJ, et al. Cloning, RNA expression, and chromosomal location of a mouse histamine H2 receptor gene. Genomics. 1996;37(3):390–4.

    Article  CAS  PubMed  Google Scholar 

  2. Fukushima Y, Shindo T, Anai M, Saitoh T, et al. Structural and functional characterization of gastric mucosa and central nervous system in histamine H2 receptor-null mice. Eur J Pharmacol. 2003;468(1):47–58.

    Article  CAS  PubMed  Google Scholar 

  3. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103(2):147–66.

    Article  CAS  PubMed  Google Scholar 

  4. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, et al. Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol. 2004;36(7):1187–205.

    Article  CAS  PubMed  Google Scholar 

  5. Nighot MP, Nighot PK, Ma TY, Malinowska DH, et al. Genetic ablation of the ClC-2 Cl- channel disrupts mouse gastric parietal cell acid secretion. PLoS One. 2015;10(9):e0138174.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Fujii T, Watanabe M, Shimizu T, Takeshima H, et al. Positive regulation of the enzymatic activity of gastric H(+),K(+)-ATPase by sialylation of its beta-subunit. Biochim Biophys Acta. 2016;1858(6):1228–35.

    Article  CAS  PubMed  Google Scholar 

  7. Wang J, Barbuskaite D, Tozzi M, Giannuzzo A, et al. Proton pump inhibitors inhibit pancreatic secretion: role of gastric and non-gastric H+/K+-ATPases. PLoS One. 2015;10(5):e0126432.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ogawa R, Echizen H. Clinically significant drug interactions with antacids: an update. Drugs. 2011;71(14):1839–64.

    Article  CAS  PubMed  Google Scholar 

  9. Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin Ther. 1996;18(1):36–54.

    Article  CAS  PubMed  Google Scholar 

  10. Deeks ED. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy. Clin Drug Investig. 2013;33(9):689–97.

    Article  CAS  PubMed  Google Scholar 

  11. Yeomans ND, Svedberg LE, Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Int J Clin Pract. 2006;60(11):1401–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Clark K, Lam LT, Gibson S, Currow D. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia. 2009;64(6):652–7.

    Article  CAS  PubMed  Google Scholar 

  13. Mills JG, Koch KM, Webster C, Sirgo MA, et al. The safety of ranitidine in over a decade of use. Aliment Pharmacol Ther. 1997;11(1):129–37.

    Article  CAS  PubMed  Google Scholar 

  14. Aouam K, Bouida W, Ben FN, Chaabane A, et al. Severe ranitidine-induced anaphylaxis: a case report and literature review. J Clin Pharm Ther. 2012;37(4):494–6.

    Article  CAS  PubMed  Google Scholar 

  15. Foti C, Cassano N, Panebianco R, Calogiuri GF, et al. Hypersensitivity reaction to ranitidine: description of a case and review of the literature. Immunopharmacol Immunotoxicol. 2009;31(3):414–6.

    Article  CAS  PubMed  Google Scholar 

  16. Davies NM, Longstreth J, Jamali F. Misoprostol therapeutics revisited. Pharmacotherapy. 2001;21(1):60–73.

    Article  CAS  PubMed  Google Scholar 

  17. Plosker GL, Lamb HM. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy. PharmacoEconomics. 1999;16(1):85–98.

    Article  CAS  PubMed  Google Scholar 

  18. Pouw RE, Bredenoord AJ. Mistakes in the use of PPIs and how to avoid them. UEG Edu. 2017;17:15–17.

    Google Scholar 

  19. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2 Suppl 1):S9–31.

    Article  CAS  PubMed  Google Scholar 

  20. Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther. 2003;17(3):343–51.

    Article  CAS  PubMed  Google Scholar 

  21. Carling L, Axelsson CK, Forssell H, Stubberod A, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther. 1998;12(10):985–90.

    Article  CAS  PubMed  Google Scholar 

  22. Chang FY, Chiang CY, Tam TN, Ng WW, et al. Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. J Gastroenterol Hepatol. 1995;10(5):595–601.

    Article  CAS  PubMed  Google Scholar 

  23. Fanti L, Ieri R, Mezzi G, Testoni PA, et al. Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. J Clin Gastroenterol. 2001;32(1):45–8.

    Article  CAS  PubMed  Google Scholar 

  24. Beker JA, Bianchi PG, Bigard MA, Delle FG, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol. 1995;7(5):407–10.

    CAS  PubMed  Google Scholar 

  25. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther. 1999;13(2):179–86.

    Article  CAS  PubMed  Google Scholar 

  26. Tulassay Z, Kryszewski A, Dite P, Kleczkowski D, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol. 2001;13(12):1457–65.

    Article  CAS  PubMed  Google Scholar 

  27. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, et al. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1998;12(8):789–95.

    Article  CAS  PubMed  Google Scholar 

  28. Regula J, Butruk E, Dekkers CP, de Boer SY, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol. 2006;101(8):1747–55.

    Article  CAS  PubMed  Google Scholar 

  29. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.

    Article  CAS  PubMed  Google Scholar 

  30. Lowe DO, Mamdani MM, Kopp A, Low DE, et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43(10):1272–6.

    Article  CAS  PubMed  Google Scholar 

  31. Danziger J, William JH, Scott DJ, Lee J, et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692–9.

    Article  CAS  PubMed  Google Scholar 

  32. William JH, Danziger J. Magnesium deficiency and proton-pump inhibitor use: a clinical review. J Clin Pharmacol. 2016;56(6):660–8.

    Article  CAS  PubMed  Google Scholar 

  33. Fallone CA, Chiba N, van Zanten SV, Fischbach L, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.

    Article  PubMed  Google Scholar 

  34. Yousfi MM, el-Zimaity HM, al-Assi MT, Cole RA, et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9(2):209–12.

    Article  CAS  PubMed  Google Scholar 

  35. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139(6):463–9.

    Article  PubMed  Google Scholar 

  36. Chen PY, Wu MS, Chen CY, Bair MJ, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44(5):427–37.

    Article  CAS  PubMed  Google Scholar 

  37. Marcus EA, Moshfegh AP, Sachs G, Scott DR. The periplasmic alpha-carbonic anhydrase activity of Helicobacter pylori is essential for acid acclimation. J Bacteriol. 2005;187(2):729–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann N Y Acad Sci. 1984;429:587–91.

    Article  CAS  PubMed  Google Scholar 

  39. Yang JC, Wang HL, Chern HD, Shun CT, et al. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. Pharmacotherapy. 2011;31(3):227–38.

    Article  CAS  PubMed  Google Scholar 

  40. Sakurai Y, Mori Y, Okamoto H, Nishimura A, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719–30.

    Article  CAS  PubMed  Google Scholar 

  41. Bi WP, Man HB, Man MQ. Efficacy and safety of herbal medicines in treating gastric ulcer: a review. World J Gastroenterol. 2014;20(45):17020–8.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Lin Y, Liao SS, Zhou YJ. Clinical study on effect of Jianwei Yuyang granule in treating patients with gastric ulcer. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007;27(7):606–9.

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors are supported by the Medical University of Lodz [502-03/1-156-04/502-14-140 to MS and #502-03/1-156-04/502-14-299 to PM] and the National Science Centre [#UMO-2015/16/T/NZ7/00031 and #UMO-2013/11/N/NZ7/02354 to MS and #UMO-2016/21/N/NZ5/01932 to PM]. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Disclosures

The authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215, Lodz, Poland

    Maciej Sałaga & Paula Mosińska

Authors
  1. Maciej Sałaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paula Mosińska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maciej Sałaga .

Editor information

Editors and Affiliations

  1. Department of Biochemistry, Medical University of Lodz, Mazowiecka, Lodz, Poland

    Jakub Fichna

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Sałaga, M., Mosińska, P. (2017). Pharmacological Treatment of Peptic Ulcer Disease. In: Fichna, J. (eds) Introduction to Gastrointestinal Diseases Vol. 2. Springer, Cham. https://doi.org/10.1007/978-3-319-59885-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59885-7_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59884-0

  • Online ISBN: 978-3-319-59885-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation